Comparing Surgical Treatment for Small NSCLC Tumors
Name of the Trial
Why This Trial Is Important
Removing just a portion of the affected lung lobe (sublobar resection) has been shown in some nonrandomized studies to result in similar rates of survival as lobectomy for patients with small tumors (2 centimeters or smaller). However, these studies were not designed to prove definitively that sublobar resection is as good as lobectomy in patients with these small tumors.
In this randomized phase III trial, patients with stage IA NSCLC measuring 2 centimeters or less and located in the outer third of the lung are randomly assigned to sublobar resection (either wedge resection or segmentectomy) or lobectomy. The researchers will follow the patients for 5 years to compare how long they live without their cancer recurring (disease-free survival). They will also compare how long the patients survive overall, their rates of lung cancer recurrence, and their lung function.
"Current practice is based on research conducted in the late 1980s," said Dr. Altorki. "We think that several developments have changed the way we should treat these small tumors. We now have much better staging and can zero in on smaller tumors on the surface of lung segments.
"If the intervention is successful, this trial is likely to change the way lung cancer is managed surgically for years to come, and this will especially benefit patients who have comorbidities such as emphysema," Dr. Altorki added.
For More Information
An archive of "Featured Clinical Trial" columns is available at http://www.cancer.gov/clinicaltrials/ft-all-featured-trials.